Notifications
Clear all
Topic starter
26/11/2022 3:44 pm
"The addition of either abiraterone, apalutamide, darolutamide or enzalutamide to ADT improves OS and failure-free survival in hormone-sensitive metastatic prostate cancer, albeit an increase in AEs."